- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04376996
Slovenian National COVID-19 Prevalence Study (SLO-COVID-19)
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that were randomly selected from the Slovenian population. The sample is representative in age, gender, and geographical distribution.
The main objective is to assess how many people in Slovenia have COVID-19 in April/May 2020 and how many were infected with SARS-CoV-2 previously.
The investigators are using a direct detection of SARS-CoV-2 RNA in nasopharyngeal samples with validated two-target PCR-based commercial assay. For a serological response to the etiological agent, IgG and IgA anti-SARS-CoV-2 antibodies are measured in plasma samples using a validated commercial assay.
Study Overview
Status
Conditions
Detailed Description
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that we have randomly selected from the Slovenian population. The sample is representative in age, gender, and geographical distribution.
The main objective is to assess how many people in Slovenia have COVID-19 in April/May 2020 and how many were infected with SARS-CoV-2 previously.
Direct detection of SARS-CoV-2 RNA in nasopharyngeal samples is performed with validated two-target PCR-based commercial assay. For a serological response to the etiological agent, IgG and IgA anti-SARS-CoV-2 antibodies are measured in plasma samples using a validated commercial assay.
Principal aims of the study are to systematically and accurately assess:
- How many people in Slovenia are actively infected with SARS CoV-2 in April/May 2020?
- How many are asymptomatic and do not even know they are or were infected?
- How many people in Slovenia have contacted SARS-CoV-2 and already have COVID-19 until mid May 2020?
The study is carried out by the Institute of Microbiology and Immunology of University of Ljubljana. The Institute is Slovenia's leading institution for microbiology and immunology research. The study is joined by a team of IT specialists, data scientists, and statisticians from the other departments of the University of Ljubljana.
To speed-up and support the study, an innovative information infrastructure for data gathering and management was purposely developed and optimized for the study. The system fosters error-free data collection, automatic processing of questionnaires using artificial intelligence approaches, and provides security for sensitive clinical data.
All participants will be passively followed up twice monthly and tested again for the presence of anti-SARS-CoV-2 antibodies in plasma samples six months after enrollment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- University of Ljubljana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Signed informed consent only.
Exclusion Criteria:
Declined participation, no response on study invitation, no samples collected.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
General cohort
General population cohort aged 0-100 years from Slovenia
|
Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples
Time Frame: April to May 2020
|
Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples
|
April to May 2020
|
Prevalence of anti-SARS-CoV-2 antibodies in blood samples
Time Frame: April to November 2020
|
Prevalence of anti-SARS-CoV-2 antibodies in blood samples
|
April to November 2020
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mario Poljak, MD, Univesity of Ljubljana, Slovenia
Publications and helpful links
General Publications
- Maver Vodicar P, Ostrbenk Valencak A, Zupan B, Avsic Zupanc T, Kurdija S, Korva M, Petrovec M, Demsar J, Knap N, Strumbelj E, Vehovar V, Poljak M. Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample. Clin Microbiol Infect. 2020 Nov;26(11):1514-1519. doi: 10.1016/j.cmi.2020.07.013. Epub 2020 Jul 18.
- Poljak M, Ostrbenk Valencak A, Strumbelj E, Maver Vodicar P, Vehovar V, Resman Rus K, Korva M, Knap N, Seme K, Petrovec M, Zupan B, Demsar J, Kurdija S, Avsic Zupanc T. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned. Clin Microbiol Infect. 2021 Jul;27(7):1039.e1-1039.e7. doi: 10.1016/j.cmi.2021.03.009. Epub 2021 Apr 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ULMF2020-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on NO intervention planned due to the observational study design - only a diagnostic testing
-
Ludwig Boltzmann Institute for Lung HealthCompletedVirus Diseases | COVID-19Austria
-
Kansas City Heart Rhythm Research FoundationRecruitingAtrial FibrillationUnited States
-
American Medical AssociationJohns Hopkins University; University of California, San Francisco; University... and other collaboratorsUnknownPhysician Work Motivation
-
Albert Einstein College of MedicineNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsRecruitingLung Diseases | Lung Diseases, Obstructive | Lung Cancer | Lung Diseases, Interstitial | Lung InflammationUnited States
-
Western Sydney Local Health DistrictUniversity of Western SydneyRecruitingHepatitis | Lung Cancer, Non-small Cell | Lung Cancer Stage IVAustralia
-
Centro Cardiologico MonzinoCompletedDepression | Quality of Life | Anxiety | Emotional Stress | Self-care | Chronic Cardiovascular DiseaseItaly
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedPulmonary Hypertension | Acute Myocardial InfarctionChina
-
Samsung Medical CenterCompletedPercutaneous Coronary Intervention | Erythrocyte Transfusion | RevascularizationKorea, Republic of
-
International Agency for Research on CancerRajiv Gandhi Centre for Biotechnology; Department of Health and Family welfare... and other collaboratorsRecruiting